These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 28499861)

  • 1. The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency.
    Cressman S; Peacock SJ; Tammemägi MC; Evans WK; Leighl NB; Goffin JR; Tremblay A; Liu G; Manos D; MacEachern P; Bhatia R; Puksa S; Nicholas G; McWilliams A; Mayo JR; Yee J; English JC; Pataky R; McPherson E; Atkar-Khattra S; Johnston MR; Schmidt H; Shepherd FA; Soghrati K; Amjadi K; Burrowes P; Couture C; Sekhon HS; Yasufuku K; Goss G; Ionescu DN; Hwang DM; Martel S; Sin DD; Tan WC; Urbanski S; Xu Z; Tsao MS; Lam S
    J Thorac Oncol; 2017 Aug; 12(8):1210-1222. PubMed ID: 28499861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
    Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
    Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
    Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
    PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
    Tammemagi MC; Schmidt H; Martel S; McWilliams A; Goffin JR; Johnston MR; Nicholas G; Tremblay A; Bhatia R; Liu G; Soghrati K; Yasufuku K; Hwang DM; Laberge F; Gingras M; Pasian S; Couture C; Mayo JR; Nasute Fauerbach PV; Atkar-Khattra S; Peacock SJ; Cressman S; Ionescu D; English JC; Finley RJ; Yee J; Puksa S; Stewart L; Tsai S; Haider E; Boylan C; Cutz JC; Manos D; Xu Z; Goss GD; Seely JM; Amjadi K; Sekhon HS; Burrowes P; MacEachern P; Urbanski S; Sin DD; Tan WC; Leighl NB; Shepherd FA; Evans WK; Tsao MS; Lam S;
    Lancet Oncol; 2017 Nov; 18(11):1523-1531. PubMed ID: 29055736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of CT screening in the National Lung Screening Trial.
    Black WC; Gareen IF; Soneji SS; Sicks JD; Keeler EB; Aberle DR; Naeim A; Church TR; Silvestri GA; Gorelick J; Gatsonis C;
    N Engl J Med; 2014 Nov; 371(19):1793-802. PubMed ID: 25372087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Lung Cancer Screening in Canada.
    Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
    JAMA Oncol; 2015 Sep; 1(6):807-13. PubMed ID: 26226181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
    Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
    J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.
    Kumar V; Cohen JT; van Klaveren D; Soeteman DI; Wong JB; Neumann PJ; Kent DM
    Ann Intern Med; 2018 Feb; 168(3):161-169. PubMed ID: 29297005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computed tomography screening for lung cancer in the National Lung Screening Trial: a cost-effectiveness analysis.
    Black WC
    J Thorac Imaging; 2015 Mar; 30(2):79-87. PubMed ID: 25635704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
    Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
    Lung Cancer; 2016 Nov; 101():98-103. PubMed ID: 27794416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria.
    Schiller-Fruehwirth I; Jahn B; Einzinger P; Zauner G; Urach C; Siebert U
    Value Health; 2017 Sep; 20(8):1048-1057. PubMed ID: 28964436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting.
    Treskova M; Aumann I; Golpon H; Vogel-Claussen J; Welte T; Kuhlmann A
    BMC Med; 2017 Aug; 15(1):162. PubMed ID: 28838313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Reduced' HUNT model outperforms NLST and NELSON study criteria in predicting lung cancer in the Danish screening trial.
    Røe OD; Markaki M; Tsamardinos I; Lagani V; Nguyen OTD; Pedersen JH; Saghir Z; Ashraf HG
    BMJ Open Respir Res; 2019; 6(1):e000512. PubMed ID: 31803478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
    Veronesi G; Navone N; Novellis P; Dieci E; Toschi L; Velutti L; Solinas M; Vanni E; Alloisio M; Ghislandi S
    Lung Cancer; 2020 May; 143():73-79. PubMed ID: 32234647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current estimate of costs of lung cancer screening in the United States.
    Mauchley DC; Mitchell JD
    Thorac Surg Clin; 2015 May; 25(2):205-15. PubMed ID: 25901564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
    Yang SC; Lai WW; Lin CC; Su WC; Ku LJ; Hwang JS; Wang JD
    Lung Cancer; 2017 Jun; 108():183-191. PubMed ID: 28625633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Economic impact of lung cancer screening in France: A modeling study].
    Gendarme S; Perrot É; Reskot F; Bhoowabul V; Fourre G; Souquet PJ; Milleron B; Couraud S
    Rev Mal Respir; 2017 Sep; 34(7):717-728. PubMed ID: 26585377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
    Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
    PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.